Volume 54, Issue 5, Pages (November 2008)

Slides:

Advertisements

Similar presentations

The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer aggressiveness de la Taille A, Irani J, Graefen.

Advertisements

Volume 61, Issue 5, Pages (May 2012)

Volume 56, Issue 5, Pages (November 2009)

Volume 72, Issue 1, Pages (July 2017)

Volume 50, Issue 3, Pages (September 2006)

Volume 59, Issue 2, Pages (February 2011)

Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes

The PSA Era is not Over for Prostate Cancer

Volume 70, Issue 6, Pages (December 2016)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 44, Issue 6, Pages (December 2003)

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 6, Pages (December 2009)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 54, Issue 4, Pages (October 2008)

Volume 66, Issue 4, Pages (October 2014)

Testosterone and Prostate Cancer: Revisiting Old Paradigms

Volume 44, Issue 1, Pages 8-16 (July 2003)

Volume 51, Issue 4, Pages (April 2007)

Volume 53, Issue 5, Pages (May 2008)

Volume 53, Issue 5, Pages (May 2008)

Volume 61, Issue 2, Pages (February 2012)

Prostate Cancer Epidemic in Sight?

Volume 61, Issue 3, Pages (March 2012)

Volume 63, Issue 4, Pages (April 2013)

Volume 50, Issue 5, Pages (November 2006)

Volume 59, Issue 2, Pages (February 2011)

Volume 54, Issue 4, Pages (October 2008)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 60, Issue 5, Pages (November 2011)

Towards Early and More Specific Diagnosis of Prostate Cancer

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 68, Issue 3, Pages (September 2015)

Volume 56, Issue 2, Pages (August 2009)

Volume 63, Issue 6, Pages (June 2013)

Luis Martínez-Piñeiro European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 66, Issue 5, Pages (November 2014)

Volume 65, Issue 2, Pages (February 2014)

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 52, Issue 2, Pages (August 2007)

Validation of Preoperative Nomograms Predicting Lymph Node Involvement in Prostate Cancer: A Bi-institutional Study Alexander I. Hinev, Vesselin I. Hadjiev,

Volume 53, Issue 4, Pages (April 2008)

Volume 61, Issue 2, Pages (February 2012)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 65, Issue 6, Pages (June 2014)

Volume 70, Issue 6, Pages (December 2016)

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 58, Issue 1, Pages (July 2010)

Volume 50, Issue 5, Pages (November 2006)

Re: Christine McKillop

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

European Urology Oncology

Prostate Cancer Nomograms: An Update

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

Volume 74, Issue 6, Pages (December 2018)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.

The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review Fritz Schröder,

Volume 68, Issue 5, Pages (November 2015)

Volume 53, Issue 2, Pages (February 2008)

Volume 74, Issue 6, Pages (December 2018)

Volume 52, Issue 5, Pages (November 2007)

Presentation transcript:

Volume 54, Issue 5, Pages 1081-1088 (November 2008) Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy Alexander Haese, Alexandre de la Taille, Hendrik van Poppel, Michael Marberger, Arnulf Stenzl, Peter F.A. Mulders, Hartwig Huland, Clément-Claude Abbou, Mesut Remzi, Martina Tinzl, Susan Feyerabend, Alexander B. Stillebroer, Martijn P.M.Q. van Gils, Jack A. Schalken European Urology Volume 54, Issue 5, Pages 1081-1088 (November 2008) DOI: 10.1016/j.eururo.2008.06.071 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 The higher the PCA3 score, the greater the probability of a positive repeat prostate biopsy. Abbreviation: PCA3, Prostate CAncer gene 3. European Urology 2008 54, 1081-1088DOI: (10.1016/j.eururo.2008.06.071) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 The diagnostic accuracy of the PCA3 assay is independent of the number of previous negative biopsies. Abbreviations: AUC, area under the curve; ROC, receiver operating characteristics. European Urology 2008 54, 1081-1088DOI: (10.1016/j.eururo.2008.06.071) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 (a) Serum total PSA level is dependent on prostate volume, whereas (b) the PCA3 score is independent of prostate volume. Median PCA3 scores: 24.4, 24.0, and 23.0 for prostate volumes <30ml, 30–50ml, and >50ml, respectively. Bars represent mean±95% CI. Abbreviations: PSA, prostate-specific antigen; PCA3, Prostate CAncer gene 3; CI, confidence interval. European Urology 2008 54, 1081-1088DOI: (10.1016/j.eururo.2008.06.071) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 4 The diagnostic accuracy of the PCA3 assay is independent of serum total PSA level. Abbreviations: PCA3, Prostate CAncer gene 3; PSA, prostate-specific antigen; AUC, area under the curve; ROC, receiver operating characteristics. European Urology 2008 54, 1081-1088DOI: (10.1016/j.eururo.2008.06.071) Copyright © 2008 European Association of Urology Terms and Conditions